A5058545802- Pneumonia and Respiratory Infections
- SARS-CoV-2 and COVID-19 Research
- Bacterial Infections and Vaccines
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- SARS-CoV-2 detection and testing
- COVID-19 epidemiological studies
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Complement system in diseases
- Advanced Biosensing Techniques and Applications
- Streptococcal Infections and Treatments
- Influenza Virus Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Zoonotic diseases and public health
- Breastfeeding Practices and Influences
- Animal Disease Management and Epidemiology
- Infant Nutrition and Health
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Diabetes and associated disorders
- Viral gastroenteritis research and epidemiology
Finnish Institute for Health and Welfare
2015-2025
Zero to Three
2021
National Institutes of Health
2012-2014
National Center for Immunization and Respiratory Diseases
2010
Centers for Disease Control and Prevention
2010
University of Alabama at Birmingham
2010
University College London
2010
Institute for Molecular Medicine Finland
2003-2007
Abstract Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order estimate the duration of immunity induced by it is important understand for how long persist after infection in humans. Here, we assessed persistence serum WT at 8 and 13 months diagnosis 367 individuals. The spike IgG (S‐IgG) nucleoprotein (N‐IgG) concentrations proportion with neutralizing (NAb) were assessed. Moreover, NAb titers among a smaller subset participants ( n = 78) against virus (B) variants...
In 2023, Finland faced an outbreak of highly pathogenic avian influenza caused by clade 2.3.4.4b A(H5N1) viruses, which spread from wild birds to fur farms. Vaccinations individuals at-risk, such as and poultry farm workers, veterinarians, laboratory began in June 2024 using the MF59-adjuvanted inactivated (H5N8) vaccine manufactured Seqirus (based on A/Astrakhan/3212/2020). We investigated antibody responses following a two-dose vaccination regimen 39 subjects. Vaccination induced...
The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) with major spike protein mutations has raised concern over potential neutralization escape and breakthrough infections among vaccinated previously SARS-CoV-2-infected subjects. We measured cross-protective antibodies against variants in health care workers (HCW, n = 20) nursing home residents (n 9) from samples collected at 1-2 months, following the booster (3rd) dose. also assessed antibody responses subjects infected before era 38)...
Antibody-mediated killing of Streptococcus pneumoniae (pneumococcus) by phagocytes is an important mechanism protection the human host against pneumococcal infections. Measurement opsonophagocytic antibodies use a standardized assay (OPA) for evaluation candidate vaccines and required licensure new conjugate vaccine formulations. We assessed agreement among six laboratories that used their own optimized OPAs on panel 16 reference sera 13 serotypes. Consensus titers, estimated using...
The licensure of new pneumococcal conjugate vaccines (PCVs) relies on immunogenicity data. When defining correlates protection, vaccine efficacy data must be included. In the FinOM Vaccine Efficacy Trial, PncOMPC showed an profile similar to that licensed PncCRM despite different antibody responses after primary and booster vaccinations. We determined kinetics avidities in a subgroup infants participating trial. A total 166 three groups were immunized at 2, 4, 6, 12 months age with 7-valent...
Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows for assessing impact epidemic containment measures and vaccinations estimating number infections regardless viral testing. We assessed antibody-mediated immunity to induced by from April 2020 December 2022 in Finland measuring serum IgG nucleoprotein (N-IgG) spike glycoprotein randomly selected 18-85-year-old subjects (n = 9794). N-IgG seroprevalence remained at <7% until last quartile (Q) 2021. After emergence...
Data on immune responses following COVID-19 booster vaccinations and subsequent infections in the immunocompromised are limited. We studied antibody after fourth dose to define patient groups benefiting most from boosters. Fourth vaccine (booster) doses were, Finland, first recommended for severely individuals, whom we invited participate our study 2022. assessed spike protein-specific IgG neutralizing antibodies (NAb) against ancestral Omicron BA.1 strains one month 488 adult participants...
In the Finnish Otitis Media Vaccine Trial, now-licensed pneumococcal conjugate vaccine containing polysaccharides conjugated to protein CRM(197) (PncCRM) and experimental polysaccharide-meningococcal outer membrane complex (PncOMPC), showed similar efficacy profiles against acute otitis media despite different antibody concentrations in sera. We now report opsonophagocytic activities (OPA) these OPA, concentration, avidity for serotypes 6B, 19F, 23F were determined sera of infants who...
Validation and standardization of accurate serological assays are crucial for the surveillance coronavirus disease 2019 (COVID-19) pandemic population immunity. We describe analytical clinical performance an in-house fluorescent multiplex immunoassay (FMIA) simultaneous quantification antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) nucleoprotein spike glycoprotein. Furthermore, we calibrated IgG-FMIA World Health Organization (WHO) International Standard compared FMIA...
Patients with chronic lymphocytic leukemia (CLL) have impaired response to vaccination, which calls for improved vaccination strategies. This study aimed evaluate antibody persistence five years after pneumococcal and revaccination. Seventyfour CLL patients 31 controls, all primary immunized 13-valent conjugated vaccine (PCV13) or 23-valent polysaccharide (PPSV23), were included. Antibody was assessed, followed by revaccination PCV13 a second PPSV23. Serological protection (SP), defined as...
In immunogenicity trials of pneumococcal conjugate vaccines (PCVs), only IgG antibody concentrations to capsular polysaccharides (PPSs) are usually determined, along with the opsonophagocytic activity (OPA) antipneumococcal antibodies. We aimed determine role both and IgM in OPA toddlers receiving one dose 9-valent PCV (PCV9). The PPSs serotypes 6A, 9V, 14, 19F, 23F were measured by enzyme immunoassay sera from (ages 18 35 months) 1 month after a single PCV9 dose. for same was multiplexed...
Dendritic cells (DCs) are largely responsible for the activation and fine-tuning of T-cell responses. Altered numbers blood DCs have been reported in type 1 diabetes (T1D). We aimed at characterizing less well-known phenotypic properties T1D.In a case-control setting, samples from total 90 children were studied by flow cytometry or quantitative real-time PCR (qPCR).We found decreased myeloid (mDCs) (8.97 vs. 13.4 cells/μL, P = 0.009, n 31) plasmacytoid (pDCs) (9.47 14.6 0.018, 30)...
ABSTRACT To provide more extensive evidence of long-term effects vaccination on immunity against Streptococcus pneumoniae , a follow-up study the Finnish Otitis Media (FinOM) Vaccine Trial was conducted. One objectives to assess persistence and avidity pneumococcal antibodies 4 years after given in infancy. Children with complete FinOM trial up 24 months age were invited single visit their fifth year life. A blood sample taken from all children for determination anticapsular antibody...
Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. In Spring 2020, we invited confirmed COVID-19 cases their household members four visits, where collected nasopharyngeal serum samples 28 days after index case onset. We calculated SAR based on presence neutralizing (NAb) assessed NAb IgG (Ab) against spike glycoprotein nucleoprotein. was 45% (39/87), including 35 symptomatic cases. During initial...
To examine how reduced iron content and added bovine lactoferrin in infant formula affect the antibody response following routine immunisation.
Abstract Understanding for how long antibodies persist following Severe acute respiratory coronavirus 2 (SARS-CoV-2) infection provides important insight into estimating the duration of immunity induced by infection. We assessed persistence serum wild-type SARS-CoV-2 six and twelve months after diagnosis in 367 individuals whom 13% had severe disease requiring hospitalization. determined spike (S-IgG) nucleoprotein IgG concentrations proportion subjects with neutralizing (NAb). also measured...
The aluminium-adjuvanted 11-valent pneumococcal conjugate vaccine containing polysaccharides 1, 4, 5, 7F, 9V, 19F, and 23F (coupled to tetanus protein) 3, 6B, 14, 18C diphtheria toxoid) elicits high antibody concentrations in Filipino infants when given at ages 6, 10, 14 weeks 9 months simultaneously with the national vaccination program. We evaluated functional activity of these antibodies by using a viable cell opsonophagocytic assay (OPA). OPA titers correlated (r=0.53–0.74) respective...
Abstract The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) with major spike protein mutations has raised concern over potential neutralization escape and breakthrough infections among vaccinated previously infected subjects. We measured cross-protective antibodies against variants in health care workers (HCW, n=20) nursing home residents (n=9) from samples collected 1-2 months following the booster (3rd) dose. also assessed antibody responses prior to era subjects (n=38) subsequent...
When measuring a functional antibody response to pneumococcal immunization, it is imperative that specific, reproducible, accurate, and standardized assay with acceptable inter- intra-assay variation be advocated internationally allow for meaningful comparison of results between laboratories. We report here the collaboration 3 international laboratories testing 30 pediatric samples against 13 serotypes in Prevenar13.
Background shared accommodation may increase the risk of SARS-CoV-2 transmission. In April 2020, an increasing number asylum seekers at a reception centre in Espoo, Finland presented with COVID-19 despite earlier implementation preventive measures. We decided to screen entire population for SARS-CoV-2. Methods we offered nasopharyngeal swab collection and real-time polymerase chain reaction (RT-PCR) analysis centre's clients. Symptoms were recorded time diagnostic sample using electronic...